1. Abstract 429: Establishment of the classifier for a response to vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma
- Author
-
M. Kang, Yong Mee Cho, Heounjeong Go, Ja-Min Park, Pil-Jong Kim, Ji Young Park, and Jae-Lyun Lee
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,biology ,Kinase ,medicine.drug_class ,business.industry ,VEGF receptors ,medicine.disease ,Tyrosine-kinase inhibitor ,Vascular endothelial growth factor ,chemistry.chemical_compound ,Oncology ,chemistry ,Renal cell carcinoma ,Partial response ,Cancer research ,medicine ,biology.protein ,business - Abstract
Vascular endothelial growth factor (VEGF)-targeted therapy has been demonstrated to improve the outcome of metastatic renal cell carcinoma (mRCC) patients. However, validated predictors that predict response and prognosis to VEGF-tyrosine kinase inhibitors (VEGF-TKIs) remain to be elucidated. We aimed to define a classifier for VEGF-TKI response in mRCC patients. Among 101 mRCC patients treated with VEGF-TKIs, 73 patients were responder defined as patients showing complete or partial response, or ≥24 weeks stable disease to VEGF-TKI; and 28 patients were nonresponder defined as Citation Format: Heounjeong Go, Mun Jung Kang, Pil-Jong Kim, Ja-Min Park, Jae-Lyun Lee, Ji Young Park, Yong Mee Cho. Establishment of the classifier for a response to vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 429.
- Published
- 2016
- Full Text
- View/download PDF